New Drugs and Clinical Research · us
Once-Monthly Subcutaneous Injection: FDA Approves Schizophrenia Drug Weltruza
A new long-acting formulation of olanzapine requires no initial loading dose, oral supplementation, or routine post-injection observation, adding another option for ongoing treatment. But more convenient administration does not eliminate weight gain and metabolic risks.
For people with schizophrenia who need long-term treatment, maintaining regular medication use can sometimes be as difficult as finding an effective drug. The U.S. Food and Drug Administration (FDA) has approved Weltruza, a once-monthly, long-acting subcutaneous injection of olanzapine, giving adult patients another option to reduce the burden of taking medication daily. Teva announced the news on October 9, 2026, and expects to launch the product in the United States in the coming weeks.
This development stems from a change in how the drug is administered. Weltruza uses Medincell’s copolymer technology to provide sustained release of the existing antipsychotic olanzapine. According to the approval information released by Teva, treatment requires no initial loading dose or supplemental oral medication, and no routine observation is required after injection. These arrangements are expected to simplify treatment initiation and monthly follow-up visits.
The approval was based on the Phase 3 SOLARIS trial. According to HCPLive, the first eight weeks of the study used a randomized, double-blind, placebo-controlled design, assigning 675 adults aged 18 to 64 to one of three dose groups or a placebo group. This was followed by a 48-week treatment period: participants who completed the initial period on active treatment continued at their existing dose, while those who completed it on placebo were randomized again to one of the three active treatment groups for further assessment of safety and tolerability.
The study assessed its primary efficacy outcome using the Positive and Negative Syndrome Scale (PANSS), with the Clinical Global Impression–Severity scale (CGI-S) and Personal and Social Performance scale (PSP) also used to measure illness severity and daily functioning. Teva said the trial showed improvements in symptoms, disease severity, and personal and social functioning. However, this announcement did not report differences in efficacy, confidence intervals, or values for the individual statistical tests. This placebo-controlled study also does not establish that the new formulation is better than oral olanzapine at preventing relapse.
Beyond convenience, safety trade-offs remain. Common adverse events in the trial included weight gain, somnolence, headache, constipation, and injection-site reactions. Weight and metabolic changes were consistent with the known risks of oral olanzapine. The proportion discontinuing treatment because of common adverse events was 5% in the active treatment groups and 4% in the placebo group; these two figures alone cannot establish that overall safety was the same. Teva’s safety information also notes that post-injection delirium/sedation syndrome has occurred with other intramuscular olanzapine formulations, while whether it could occur with Weltruza remains unclear. The absence of a requirement for routine observation does not mean this risk has been ruled out.
Reuters reported that Teva leads the development and commercialization of Weltruza, which is the second product approved in the United States under the two companies’ collaboration, following the long-acting risperidone injection Uzedy, approved in 2023. In Europe, regulators accepted Weltruza’s marketing application in May 2026, but it has not yet been approved. This U.S. approval adds monthly subcutaneous administration to the clinical options available; how much it can improve treatment persistence and reduce relapse in routine care still requires evidence from actual use after launch.